Mode
Text Size
Log in / Sign up
N/A N=80 Randomized Treatment

Trial Comparing BST-CarGel and Microfracture in Repair of Articular Cartilage Lesions in the Knee

Knee Injuries

Enrolled (actual)
80
Serious AEs
7.5%
Results posted
Dec 2015
Primary outcome: Primary: Degree of Filling of the Lesion by Repair Tissue at 12 Months Through MRI. — 92.81; 85.22 Percentage of lesion fill — p=0.011

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
BST-CarGel with Microfracture (Device); Microfracture without BST-CarGel (Procedure)
Age
Adult · 18+ yrs
Sex
All
Sponsor
Piramal Healthcare Canada Ltd
Primary completion
Feb 2011

Outcome Measures

OutcomeResultp-value
PRIMARY
Degree of Filling of the Lesion by Repair Tissue at 12 Months Through MRI.
92.81; 85.22 0.011 sig
PRIMARY
Repair Cartilage T2 Relaxation Time
70.46; 85.04 0.033 sig
SECONDARY
Change From Baseline for Knee-related Pain, Stiffness and Function at 12 Months (WOMAC Parts A, B, C)
-16.16; -16.91; -5.97; -6.56; -55.96; -60.59
SECONDARY
Frequency of Adverse Events Between Study Groups
97.6; 92.3

Summary

This study will investigate whether the treatment of damaged cartilage in the knee with BST-CarGel will increase the amount and quality of cartilage repair tissue when compared with microfracture alone. Furthermore, the effect of BST-CarGel in decreasing cartilage related pain and improving cartilage-related function in the knee will be assessed.

Eligibility Criteria

Inclusion Criteria

  • Between 18 and 55 years of age
  • Focal articular cartilage lesion on the medial femoral condyle
  • Grade 3 or 4 acute (traumatic) or chronic (degenerative) lesion
  • Stable knee

Exclusion Criteria

  • Multiple lesions or kissing lesions
  • Clinically relevant compartment malalignment (> 5 degrees)
  • Undergone ligament treatments in the affected knee within 2 years prior to trial
  • Inflammatory arthropathy, such as rheumatoid arthritis, systemic lupus, or active gout
  • Previous surgical cartilage treatments in the affected knee in the last 12 months
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00314236). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search